Business Description
Thiogenesis Therapeutics Corp
NAICS : 325410
SIC : 3741
ISIN : CA88410L1022
Description
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.22 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -166.8 | |||||
3-Year EPS without NRI Growth Rate | -164.5 | |||||
3-Year FCF Growth Rate | -295.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.8 | |||||
9-Day RSI | 27.37 | |||||
14-Day RSI | 36.85 | |||||
3-1 Month Momentum % | 13.2 | |||||
6-1 Month Momentum % | -25.68 | |||||
12-1 Month Momentum % | -83.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.82 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -679.52 | |||||
ROA % | -300.05 | |||||
ROCE % | -674.84 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.83 | |||||
EV-to-EBIT | -4.09 | |||||
EV-to-Forward-EBIT | -2.62 | |||||
EV-to-EBITDA | -4.09 | |||||
EV-to-Forward-EBITDA | -2.62 | |||||
EV-to-FCF | -4.76 | |||||
Earnings Yield (Greenblatt) % | -24.45 | |||||
FCF Yield % | -20.36 |
GF Valueâ„¢
Thiogenesis Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thiogenesis Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guru Commentaries on OTCPK:TTIPF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Thiogenesis Therapeutics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers